Clinical relevance of galectin-1 expression in non-small cell lung cancer patients

Carlini, Maria J.; Roitman, Pablo; Núñez, Margarita Ostrowski de; Pallotta, María Guadalupe; Boggio, G.; Smith, David; Salatino, Mariana; Joffé, Elisa D. Bal de Kier; Rabinovich, Gabriel A.; Puricelli, Lydia

doi:10.1016/j.lungcan.2014.01.016

Cited by 38 publications

(30 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kim et al 11 showed that Gal-1 significantly induced cell proliferation and invasion in epithelial ovarian cancer cells. In various tumours, Gal-1 overexpression has been shown to be associated with poor prognosis,11 30 31 tumour invasiveness17 19 and tumour grade 32. In recent years, the clinicopathological significance of Gal-1 expression in head and neck SCC (HNSCC) has been reported.…”

Section: Discussionmentioning

confidence: 99%

Galectin-1 expression is associated with tumour immunity and prognosis in gingival squamous cell carcinoma

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Galectin-1 expression is associated with tumour immunity and prognosis in gingival squamous cell carcinoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…54,55 Carlini et al proposed that galectin-1 may be used as a potential biomarker to better predict the clinical outcome and management of NSCLC patients. 56 Since the aforementioned works were performed in cell lines and tumor tissues, the decreased level of galectin-1 in blood from early stage patients (stages I and II) may result from its intracellular accumulation, which could contribute to promoting tumor growth. The lower expression level in blood has been verified by ELISA here, and the mechanism and potential application await elucidation by further studies.…”

Section: ■ Discussionmentioning

confidence: 99%

Qualification and Verification of Serological Biomarker Candidates for Lung Adenocarcinoma by Targeted Mass Spectrometry

Goan

Chang

et al. 2015

J. Proteome Res.

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer mortality worldwide. Although many biomarkers have been identified for lung cancer, their low specificity and sensitivity present an urgent need for the identification of more candidate biomarkers. In this study, we conducted MRM-based targeted analysis to evaluate the potential utility of a list of candidate proteins for lung cancer diagnosis. A total of 1249 transitions of 420 peptides representing 102 candidate proteins from our previous study and the literature were first screened by MRM analysis in pooled plasma samples, resulting in 78 proteins remaining in the list. Relative quantification of these 78 proteins was further performed in 60 individual plasma samples from lung adenocarcinoma patients in stages I-III and matched healthy control subjects. Ultimately, nine proteins were found to be able to distinguish patients from controls. Further combinations of five, three, and two candidate marker proteins improved the sensitivity to discriminate patients from controls and resulted in a merged AUC value of nearly 1.00 in stages I-III patients versus controls. Our results highlighted several possible markers for lung adenocarcinoma, and the proposed protein panels require further validation in a larger cohort to evaluate their potential use in clinical applications or development of therapeutics.

show abstract

“…Гелзолин, выполняющий функцию актин-связывающего белка, ранее уже рассматривался в качестве кандидатного маркера для многих типов опухолей, в том числе рака молочной железы, толстой кишки, предстательной железы, мочевого пузыря и рака лёгких [84][85][86][87][88]. Галектин 1, участвующий в регуляции апоптоза, пролиферации и дифференцировки клеток, в случае АКЛ задействован в миграции клеток, инвазии и опухолевой прогрессии [89,90]. Цитоплазматический актин 1 участвует во множестве процессов, связанных с подвижностью клеток, его экспрессия была повышена у пациентов на всех стадиях АКЛ по сравнению со здоровым контролем [39].…”

Section: направленный масс-спектрометрический анализunclassified

Omics technologies in diagnostics of lung adenocarcinoma

et al. 2017

View full text Add to dashboard Cite

To date lung adenocarcinoma (LAC) is the most common type of lung cancer. Numerous studies on LAC biology resulted in identification of crucial mutations in protooncogenes and activating neoplastic transformation pathways. Therapeutic approaches that significantly increase the survival rate of patients with LAC of different etiology have been developed and introduced into clinical practice. However, the main problem in the treatment of LAC is early diagnosis, taking into account both factors and mechanisms responsible in tumor initiation and progression. Identification of a wide biomarker repertoire with high specificity and reliability of detection appears to be a solution to this problem. In this context, proteins with differential expression in normal and pathological condition, suitable for detection in biological fluids are the most promising biomarkers. In this review we have analyzed literature data on studies aimed at search of LAC biomarkers. The major attention has been paid to protein biomarkers as the most promising and convenient subject of clinical diagnosis. The review also summarizes existing knowledge on posttranslational modifications, splice variants, isoforms, as well as model systems and transcriptome changes in LAC.

show abstract

Clinical relevance of galectin-1 expression in non-small cell lung cancer patients

Abstract: We conclude that Gal-1 expression may be a useful biomarker for better prediction of the clinical outcome and management of NSCLC patients.

Cited by 38 publications

References 30 publications

Galectin-1 expression is associated with tumour immunity and prognosis in gingival squamous cell carcinoma

Galectin-1 expression is associated with tumour immunity and prognosis in gingival squamous cell carcinoma

Qualification and Verification of Serological Biomarker Candidates for Lung Adenocarcinoma by Targeted Mass Spectrometry

Omics technologies in diagnostics of lung adenocarcinoma

Contact Info

Product

Resources

About